Atlas Trials

Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.

Clinical trial NCT03983096 · COMPLETED

Trial details

NCT number
NCT03983096
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
COMPLETED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2019-07-07
Primary completion
2020-05-01
Enrollment
1213

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.